All that is true, but that another problem for the FDA to address separately.
Specifically to Ryoncil, what we have here is someone who clearly did not follow the protocol and then used his base to further discuss the need for RCT.
In this case, it didn't end up influencing anyone else, but it could have.
As a minimum, Mesoblast has another point of dispute to include in the Type A request!
Conflict of Interest Evidence Thread - C. Hinrichs in ODAC Meeting, page-28
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.5¢ | 91.5¢ | $381.1K | 414.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 170161 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 41927 | 17 |
View Market Depth
| Last trade - 10.45am 18/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |